Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
暂无分享,去创建一个
N. Spector | Wenle Xia | Lei-hua Liu | W. Xia | Neil L Spector | Lei-Hua Liu | Peter Ho | P. Ho
[1] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[2] E. Wagner,et al. Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.
[3] P. Brandt-Rauf,et al. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. , 1995, Mutation research.
[4] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[5] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[6] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[7] Monilola A. Olayioye,et al. ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.
[8] J. Testa,et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival , 2002, Oncogene.
[9] Hong Ma,et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.
[10] A. Harris,et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.
[11] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[12] W. Gullick,et al. The type I growth factor receptors in human breast cancer , 2004, Breast Cancer Research and Treatment.
[13] M. Luther,et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[14] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[15] L. Cantley,et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.
[16] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[17] J. Cheng,et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Gelman,et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. O'hare,et al. New model of ErbB‐2 over‐expression in human mammary luminal epithelial cells , 1999, International journal of cancer.
[20] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[21] D. Stern,et al. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.
[22] A. Ullrich,et al. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. , 1999, Current opinion in cell biology.
[23] I. Stamenkovic. Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.
[24] M. Greene,et al. Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.
[25] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[26] S. Aaronson,et al. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.
[27] D. Barnes,et al. Expression of the ERBB3 gene product in breast cancer. , 1992, British Journal of Cancer.
[28] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[29] Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. , 2001, Bioorganic & medicinal chemistry letters.
[30] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[32] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Lupu,et al. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer , 2003, Oncogene.
[34] Y. Yarden,et al. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2 , 1995, Molecular and cellular biology.
[35] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[36] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[37] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[38] L. Seymour,et al. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. , 1994, British journal of cancer.
[39] W. Gullick,et al. Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.
[40] Cori Bargmann,et al. Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.